Pancreatic Cancer Clinical Trial
Official title:
Low Dose Multi-arterial Phase CT Imaging for Improved Detection of Liver Tumors and Pancreatic Masses
Verified date | March 2021 |
Source | Karolinska Institutet |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
To examine inter-subject variations of optimal late arterial phase contrast-enhancement defined as the greatest difference in contrast attenuation of hepatocellular carcinoma (HCC) compared to background liver parenchyma resp. pancreatic lesions compared to pancreatic parenchyma. To evaluate which time-points best depict an optimal late arterial phase.
Status | Active, not recruiting |
Enrollment | 50 |
Est. completion date | May 2021 |
Est. primary completion date | January 26, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: - patients, who are scheduled for a multiphasic liver or pancreas CT because of known or suspected malignancy in the liver or pancreas. Exclusion Criteria: - below 50 years of age, contrast media allergy or decreased kidney function |
Country | Name | City | State |
---|---|---|---|
Sweden | Radiology Department, Karolinska Huddinge university hospital | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Karolinska Institutet |
Sweden,
Bae KT, Heiken JP. Scan and contrast administration principles of MDCT. Eur Radiol. 2005 Dec;15 Suppl 5:E46-59. Review. — View Citation
Bae KT. Intravenous contrast medium administration and scan timing at CT: considerations and approaches. Radiology. 2010 Jul;256(1):32-61. doi: 10.1148/radiol.10090908. Review. — View Citation
Delrue L, Blanckaert P, Mertens D, De Waele J, Ceelen W, Achten E, Duyck P. Variability of CT contrast enhancement in the pancreas: a cause for concern? Pancreatology. 2011;11(6):588-94. doi: 10.1159/000334547. Epub 2012 Jan 11. — View Citation
Fleischmann D, Kamaya A. Optimal vascular and parenchymal contrast enhancement: the current state of the art. Radiol Clin North Am. 2009 Jan;47(1):13-26. doi: 10.1016/j.rcl.2008.10.009. Review. — View Citation
Goshima S, Kanematsu M, Kondo H, Yokoyama R, Miyoshi T, Nishibori H, Kato H, Hoshi H, Onozuka M, Moriyama N. MDCT of the liver and hypervascular hepatocellular carcinomas: optimizing scan delays for bolus-tracking techniques of hepatic arterial and portal venous phases. AJR Am J Roentgenol. 2006 Jul;187(1):W25-32. — View Citation
Heiken JP, Brink JA, McClennan BL, Sagel SS, Crowe TM, Gaines MV. Dynamic incremental CT: effect of volume and concentration of contrast material and patient weight on hepatic enhancement. Radiology. 1995 May;195(2):353-7. — View Citation
Ichikawa T, Erturk SM, Araki T. Multiphasic contrast-enhanced multidetector-row CT of liver: contrast-enhancement theory and practical scan protocol with a combination of fixed injection duration and patients' body-weight-tailored dose of contrast material. Eur J Radiol. 2006 May;58(2):165-76. Epub 2006 Jan 18. Review. — View Citation
Kondo H, Kanematsu M, Goshima S, Miyoshi T, Shiratori Y, Onozuka M, Moriyama N, Bae KT. MDCT of the pancreas: optimizing scanning delay with a bolus-tracking technique for pancreatic, peripancreatic vascular, and hepatic contrast enhancement. AJR Am J Roentgenol. 2007 Mar;188(3):751-6. — View Citation
Rengo M, Bellini D, De Cecco CN, Osimani M, Vecchietti F, Caruso D, Maceroni MM, Lucchesi P, Iafrate F, Palombo E, Paolantonio P, Ferrari R, Laghi A. The optimal contrast media policy in CT of the liver. Part II: Clinical protocols. Acta Radiol. 2011 Jun 1;52(5):473-80. doi: 10.1258/ar.2011.100500. Epub 2011 Mar 28. Review. — View Citation
Rengo M, Bellini D, De Cecco CN, Osimani M, Vecchietti F, Caruso D, Maceroni MM, Lucchesi P, Iafrate F, Paolantonio P, Ferrari R, Laghi A. The optimal contrast media policy in CT of the liver. Part I: Technical notes. Acta Radiol. 2011 Jun 1;52(5):467-72. doi: 10.1258/ar.2011.100499. Epub 2011 Mar 17. Review. — View Citation
Schueller G, Schima W, Schueller-Weidekamm C, Weber M, Stift A, Gnant M, Prokesch R. Multidetector CT of pancreas: effects of contrast material flow rate and individualized scan delay on enhancement of pancreas and tumor contrast. Radiology. 2006 Nov;241(2):441-8. Epub 2006 Sep 18. — View Citation
Tang A, Billiard JS, Chagnon DO, Rizk F, Olivié D, Turcotte S, Chagnon M, Lepanto L. Optimal Pancreatic Phase Delay with 64-Detector CT Scanner and Bolus-tracking Technique. Acad Radiol. 2014 Aug;21(8):977-85. doi: 10.1016/j.acra.2014.04.004. — View Citation
* Note: There are 12 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Peak enhancement values measured in Hounsfield units(HU) in abdominal aorta. | Creation of time attenuation curves (TAC) in abdominal aorta. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement times measured in seconds in abdominal aorta. | Creation of time attenuation curves (TAC) in abdominal aorta. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement values measured in Hounsfield units(HU) in celiac trunc. | Creation of time attenuation curves (TAC) in celiac trunc. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement times measured in seconds in celiac trunc. | Creation of time attenuation curves (TAC) in celiac trunc. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement values measured in Hounsfield units(HU) in superior mesenteric artery (SMA). | Creation of time attenuation curves (TAC) in SMA. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement times measured in seconds in superior mesenteric artery (SMA). | Creation of time attenuation curves (TAC) in SMA. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement values measured in Hounsfield units(HU) in hepatic artery. | Creation of time attenuation curves (TAC) in hepatic artery. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement times measured in seconds in hepatic artery. | Creation of time attenuation curves (TAC) in hepatic artery. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement values measured in Hounsfield units(HU) in portal vein. | Creation of time attenuation curves (TAC) in portal vein. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement times measured in seconds in portal vein. | Creation of time attenuation curves (TAC) in portal vein. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement values measured in Hounsfield units(HU) in pancreas parenchyma. | Creation of time attenuation curves (TAC) in pancreas parenchyma. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement values measured in Hounsfield units(HU) in pancreatic lesions. | Creation of time attenuation curves (TAC) in pancreatic lesions. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement times measured in seconds in pancreas parenchyma. | Creation of time attenuation curves (TAC) in pancreas parenchyma. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement times measured in seconds in pancreatic lesions. | Creation of time attenuation curves (TAC) in pancreatic lesions. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement values measured in Hounsfield units(HU) in liver parenchyma. | Creation of time attenuation curves (TAC) in liver parenchyma. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement values measured in Hounsfield units(HU) in hepatic lesions. | Creation of time attenuation curves (TAC) in hepatic lesions. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement times measured in seconds in liver parenchyma. | Creation of time attenuation curves (TAC) in liver parenchyma. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | Peak enhancement times measured in seconds in hepatic lesions. | Creation of time attenuation curves (TAC) in hepatic lesions. | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | highest enhancement difference between a hepatic lesion and background liver parenchyma | To measure the highest enhancement difference in Hounsfield units(HU) between a hepatic lesion and background liver parenchyma | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | time-point of highest enhancement difference between a hepatic lesion and background liver parenchyma | To depict the time-point of the highest enhancement difference between a hepatic lesion and background liver parenchyma by comparing their tissue attenuation curves | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | highest enhancement difference between a pancreatic lesion and background pancreatic parenchyma | To measure the highest enhancement difference in Hounsfield units(HU) between a pancreatic lesion and background pancreas parenchyma | at the time of intervention (= Multi-phasic CT scan of the abdomen) | |
Primary | time-point of highest enhancement difference between a pancreatic lesion and background pancreatic parenchyma | To depict the time-point of the highest enhancement difference between a pancreatic lesion and background pancreas parenchyma by comparing their tissue attenuation curves | at the time of intervention (= Multi-phasic CT scan of the abdomen) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|